Atopic Dermatitis

>

Latest News

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

June 27th 2025

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis | Image credit: Weill Cornell Medicine
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis

June 25th 2025

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics.
FDA extends review of ruxolitinib cream for pediatric atopic dermatitis

June 20th 2025

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

June 13th 2025

First infant enrolled in trial of roflumilast 0.05% for atopic dermatitis in infants | | Image Credit: © Dinko - © Dinko- stock.adobe.com.
First infant enrolled in trial of roflumilast cream, 0.05% for atopic dermatitis in infants

June 10th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.